Stock Analysis

High Growth Tech Stocks In US With Promising Potential

NasdaqGM:VNDA
Source: Shutterstock

Over the last 7 days, the United States market has experienced a 3.0% drop, yet it remains up by 7.5% over the past year with earnings anticipated to grow by 14% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that exhibit strong innovation and adaptability to capitalize on these projected earnings growth trends.

Top 10 High Growth Tech Companies In The United States

NameRevenue GrowthEarnings GrowthGrowth Rating
Super Micro Computer20.44%29.79%★★★★★★
TG Therapeutics26.18%37.61%★★★★★★
Alkami Technology20.46%85.16%★★★★★★
Travere Therapeutics28.40%64.74%★★★★★★
Clene60.86%63.07%★★★★★★
Alnylam Pharmaceuticals22.69%58.49%★★★★★★
AVITA Medical27.91%55.77%★★★★★★
TKO Group Holdings22.48%25.17%★★★★★★
Lumentum Holdings21.55%119.67%★★★★★★
Ascendis Pharma32.36%59.79%★★★★★★

Click here to see the full list of 238 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

BigCommerce Holdings (NasdaqGM:BIGC)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BigCommerce Holdings, Inc. provides a software-as-a-service ecommerce platform for brands and retailers across various regions globally, with a market cap of $452.74 million.

Operations: The company generates revenue primarily from its software-as-a-service ecommerce platform, with $332.93 million attributed to Internet Information Providers.

BigCommerce Holdings is positioning itself as a pivotal player in the digital transformation of the electrical distribution industry through its strategic partnership with NAED. This collaboration, aimed at fostering innovation and workforce development, underscores BigCommerce's commitment to enhancing its B2B commerce capabilities for manufacturers and distributors. The company's recent executive hires, including SaaS veteran Andrew Norman to spearhead EMEA operations, further signal its intent to expand and adapt in a competitive market. Despite reporting a narrowed net loss from $64.67 million to $27.03 million year-over-year and an increase in annual sales to $332.93 million, BigCommerce's revenue growth projection of 5.2% trails the U.S market average of 8.3%. However, with anticipated earnings growth of 47.27% per year and strategic initiatives like the transformative partnership with Pipe17 enhancing order management efficiencies, BigCommerce is crafting a robust foundation for future profitability and market relevance.

NasdaqGM:BIGC Revenue and Expenses Breakdown as at Apr 2025
NasdaqGM:BIGC Revenue and Expenses Breakdown as at Apr 2025

Vanda Pharmaceuticals (NasdaqGM:VNDA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of $267.67 million.

Operations: Vanda Pharmaceuticals generates revenue primarily from its biotechnology segment, amounting to $198.77 million. The company focuses on developing and commercializing therapies for unmet medical needs globally.

Vanda Pharmaceuticals is navigating a dynamic phase with its recent submission of a New Drug Application for Bysanti, targeting acute bipolar I disorder and schizophrenia, demonstrating an aggressive push into new therapeutic areas. This move aligns with an impressive projected annual revenue growth of 28.8%, outpacing the broader U.S. market's 8.3% growth rate. Despite current unprofitability, Vanda's strategic R&D investments are set to foster significant earnings growth, estimated at 58.32% annually, positioning it well for future profitability within three years. The company's focus on innovative treatments for complex psychiatric and neurological conditions underscores its commitment to addressing unmet medical needs through targeted research and development efforts.

NasdaqGM:VNDA Revenue and Expenses Breakdown as at Apr 2025
NasdaqGM:VNDA Revenue and Expenses Breakdown as at Apr 2025

Gannett (NYSE:GCI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gannett Co., Inc. is a media and digital marketing solutions company based in the United States with a market capitalization of approximately $413.87 million.

Operations: Gannett generates revenue primarily through its Domestic Gannett Media segment, which accounts for $1.94 billion, and its Digital Marketing Solutions segment, contributing $477.81 million. The company operates within the media and digital marketing sectors in the U.S., focusing on delivering content and marketing services across various platforms.

Gannett's strategic maneuvers, including the recent appointment of Trisha Gosser as CFO and proactive debt reduction by prepaying $57.5 million, underscore its commitment to financial stability and operational efficiency. Despite a projected annual revenue decline of 2.5%, Gannett is poised for significant earnings growth, with forecasts suggesting an increase of 92% annually. This growth trajectory is supported by innovative partnerships, like the one with Reuters, enhancing Gannett's digital content distribution capabilities and potentially increasing its market footprint in the evolving media landscape.

NYSE:GCI Earnings and Revenue Growth as at Apr 2025
NYSE:GCI Earnings and Revenue Growth as at Apr 2025

Taking Advantage

  • Gain an insight into the universe of 238 US High Growth Tech and AI Stocks by clicking here.
  • Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
  • Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

If you're looking to trade Vanda Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com